世界卫生组织：基于GLP-1疗法治疗成人肥胖症的新指南计划9月份正式发布

Core Viewpoint - The World Health Organization (WHO) is developing new guidelines for the treatment of adult obesity based on GLP-1 therapies, set to be officially released in September 2025, marking a significant policy shift in addressing the global obesity crisis [1] Group 1: Guidelines Development - The guidelines are being created by an independent guideline development group (GDG) consisting of experts in obesity, epidemiology, clinical management, pharmacology, health economics, public health programs, and policymakers to ensure adherence to WHO's strict standards [1] - The purpose of the guidelines is to clarify the clinical indications, applications, and planning considerations for GLP-1 receptor agonists (GLP1RAs) [1] Group 2: Implications - This will be the first time the WHO officially recommends the use of weight-loss medications for treating adult obesity, indicating a major shift in the organization's approach to the obesity crisis [1]